Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by DAVA Oncology on X, adding:
“FourLight-3, a phase 3 study to look at the selective CDK4i Atirmociclib + AI vs treatment physician choice CDK4/6i (ribo, palbo, abema) in 1st line HR+/HER2- a/mBC.”
Quoting DAVA Oncology‘s post:
“Can selective CDK4 inhibition improve outcomes in HR+/HER2– BC?
Atirmociclib showed manageable safety in Phase 1/2A. The Phase 3 FourLight-3 trial now tests it head-to-head vs CDK4/6i in 1L.”
More posts featuring Antonio Giordano on OncoDaily.
